An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia

Current Medical Research and Opinion

Volumn 23, Issue 1, 2007, Pages 97-104

  Tunis, Sandra L ^a   Faries, Douglas E ^b   Stensland, Michael D ^b   Hay, Donald P ^c   Kinon, Bruce J ^b  

^a IQVIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c WISHARD HEALTH SERVICES   (United States)

Author keywords

Adherence; Antipsychotic; Medication persistence; Olanzapine; Risperidone; Schizophrenia; Substance abuse; Therapeutic alliance

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MEDICAL RECORD; MEDICAL STAFF; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIFORM DISORDER; SELF REPORT; SUBSTANCE ABUSE; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; PATIENT COMPLIANCE; RISPERIDONE; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 33846668904     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X162665     Document Type: Article

References (56)

1. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(Suppl):1-56
2. Lehman AF, Steinwachs DM; co-investigators of PORT project. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998;24:1-10
3. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52:805-11
4. Harman JS, Manning WG, Lurie N, et al. Association between interruptions in Medicaid coverage and use of inpatient psychiatric services. Psychiatr Serv 2003;54:999-1005
5. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-91
6. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-57
7. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003;29:15-31
8. McCombs JS, Nichol MB, Johnstone BM, et al. Antipsychotic drug use patterns and cost of treating schizophrenia. Psychiatr Serv 2000;51:525-7
9. Johnsrud M, Schafermeyer KW. Measuring adherence and persistence in drug therapy. J Man Care Pharm 2002;8:204-6
10. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff 2004;23:135-46
11. Ray WA, Daugherty JR, Meador KG. Effect of a mental health 'carve-out' program on the continuity of antipsychotic therapy. N Engl J Med 2003;348:1885-94
12. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
13. Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics 2000;18:106-24
14. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909
15. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13:177-83
16. Awad AG, Voruganti LN, Heslegrave RJ, et al. Assessment of the patient's subjective experience in acute neuroleptic treatment: Implications for compliance and outcome. Int Clin Psychopharmacol 1996;11(Suppl 2):55-9
17. Garavan J, Browne S, Gervin M, et al. Compliance with neuroleptic medication in outpatients with schizophrenia: relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr Psychiatry 1998;39:215-9
18. Awad AG, Hogan TP, Voruganti LN, et al. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 1995;10(Suppl 3):123-32
19. Hay DP, Hay L, Renner J, et al. Compliance and the treatment alliance in the elderly patient with severe mental illness. In: Blackwell B, editor. Treatment compliance and therapeutic alliance. Amsterdam: Harwood Academic Publishers, 1997
20. Horvath AO. The therapeutic relationship: from transference to alliance. J Clin Psychol 2000;56:163-73
21. Frank AF, Gunderson JG. The role of the therapeutic alliance in the treatment of schizophrenia. Relationship to course and outcome. Arch Gen Psychiatry 1990;47:228-36
22. Martin DJ, Garske JP, Davis MK. Relation of the therapeutic alliance with outcome and other variables: a meta-analytic review. J Consult Clin Psychol 2000;68:438-50
23. Olfson M, Mechanic D, Hansell S, et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51:216-22
24. Drake RE, Wallach MA. Dual diagnosis: 15 years of progress. Psychiatr Serv 2000;51:1126-9
25. Margolese HC, Malchy L, Negrete JC, et al. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res 2004;67:157-66
26. Smelson D, Nyhuis AW, Faries DE, et al. Impact of substance use on attrition and medication switching in an effectiveness trial for individuals with schizophrenia: implications for relapse prevention. Poster presentation at the American Psychopathological Association. New York, NY, USA. February, 2005
27. Buckley PF. Novel antipsychotic medications and the treatment of comorbid substance abuse in schizophrenia. J Subst Abuse Treat 1998;15:113-6
28. Kamali M, Kelly L, Gervin M, et al. Psychopharmacology: insight and comorbid substance misuse and medication compliance among patients with schizophrenia. Psychiatr Serv 2001;52:161-6
29. Drake RE, Osher FC, Wallach MA. Alcohol use and abuse in schizophrenia. A prospective community study. J Nerv Ment Dis 1989;177:408-14
30. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res 1999;35:S93-100
31. Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res 2002;54:253-64
32. Ruscher SM, de Wit R, Mazmanian D. Psychiatric patients' attitudes about medication and factors affecting noncompliance. Psychiatr Serv 1997;48:82-5
33. Gerlach J. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment. J Clin Psychiatry 1999;23(Suppl 60):20-4
34. Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103-8
35. Glick ID, Berg PH. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. Int Clin Psychopharmacol 2002;17:65-8
36. Menzin J, Boulanger L, Friedman M, et al. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 2003;54:719-23
37. Hugenholtz GW, Heerdink ER, Nolen WA, et al. Less medication switching after initial start with atypical antipsychotics. Eur Neuropsychopharmacol 2004;14:1-5
38. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
39. Zhao Z, Tunis SL, Lage MJ. Medication treatment patterns following initiation on olanzapine versus risperidone. Clin Drug Invest 2002;22:741-9
40. Bagnall AM, Jones L, Ginnelly L, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess 2003;7:1-193
41. Santarlasci B, Messori A. Clinical trial response and dropout rates with olanzapine versus risperidone. Ann Pharmacother 2003;37:556-63
42. Zhao Z, Namjoshi M, Barber BL, et al. Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database. CNS Drugs 2004;18:157-64
43. Tunis SL, Johnstone BM, Kinon BJ, et al. Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapies. Value Health 2000;3:232-42
44. Tunis SL, Faries DE, Nyhuis AW, et al. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health 2006;9:77-89
45. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). Washington DC: The Association, 1994
46. First M, Spitzer R, Gibbon M, et al. Structured clinical interview for DSM-IV axis I disorders-administration booklet. Washington, DC: American Psychiatric Press, 1994
47. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799-812
48. Weiden P, Rapkin B, Zygmunt A, et al. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv 1995;46:1049-54
49. Bloch Y, Mendlovic S, Strupinsky S, et al. Injections of depot antipsychotic medications in patients suffering from schizophrenia: Do they hurt? J Clin Psychiatry 2001;62:855-9
50. Weiden P, Rapkin B, Mott T, et al. Rating of Medication Influences (ROMI) scale in schizophrenia. Schizophr Bull 1994;20:297-310
51. McCombs JS, Luo M, Johnstone BM, et al. The use of conventional antipsychotic medications for patients with schizophrenia in a Medicaid population: therapeutic and cost outcomes over 2 years. Value Health 2000;3:222-31
52. Rascati KL, Johnsrud MT, Crismon ML, et al. Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid patients. Pharmacoeconomics 2003;21:683-97
53. Cramer J, Rosenheck R, Kirk G, et al. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003;6:566-73
54. SAS Institute. SAS/STAT user's guide. Cary, NC, USA: SAS Institute, 1999
55. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-51
56. Lehman AF. Developing an outcomes-oriented approach for the treatment of schizophrenia. J Clin Psychiatry 1999;60(Sup 19):30-5